Technical Data
C3g (iC3, iC3b, C3dg)
C3g itself however is a small fragment probably not formed in vivo. The complement system is an important factor in innate immunity. The third complement component, C3, is central to the classical, alternative and lectin pathways of complement activation. Activation products of the complement cascade contain neo-epitopes that are not present in the individual native components. The synthesis of C3 is tissue-specific and is modulated in response to a variety of stimulatory agents. C3 is the most abundant protein of the complement system with serum protein levels of about 1.3mg/ml. An inherited deficiency of C3 predisposes the person to frequent bacterial infections. C3 fragments are deposited in tissues at sites of antibody-mediated immunopathology. In ulcerative colitis and idiopathic chronic inflammatory bowel disease, the deposition of C3 in the diseased mucosa has been reported. Proteolysis by C3-convertases results in the cleavage of C3 into C3a and C3b. C3b becomes attached to immune complexes and is further cleaved into iC3b and C3f. iC3b is further processed into C3c and C3dg. C3dg can be cleaved into C3d and C3g though this does not occur in plasma.

Suitable for use in Immunoprecipitation and ELISA. Other applications not tested.

Recommended Dilution:
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
MabIgG113A21Affinity Purified
100ug-20CBlue IceHumanRat
Purified by Protein G affinity chromatography.
Supplied as a liquid in PBS, 0.1% BSA, 0.02% sodium azide.
Recognizes a neoantigen on iC3, iC3b, C3dg and C3g in plasma. Does not recognize C3 or C3b.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Lachmann, P et al; Three monoclonal antibodies to human C3. Immunology 1980, 41: 503. 2. Lachmann, P et al; Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies. J Exp Med 1982, 156: 205. 3. Lachmann, P et al; Use of monoclonal anti-C3 antibodies to characterise the fragments of C3 that are found on erythrocytes. Vox Sang 1983, 45: 367. 4. Chaplin, H et al; Further studies of the C3g component of the alpha 2D fragment of human C3. Clin Exp Immunol 1983, 51: 639. 5. Mollnes, T et al; Activation of the third component of complement (C3) detected by a monoclonal anti-C3'g' neoantigen antibody in a one-step enzyme immunoassay. J Immunol Methods 1987, 101: 201.